ceclazepide

Ceclazepide is a novel small molecule prodrug that acts as a selective gastrin/CCKB (cholecystokinin B) receptor antagonist. It is designed to efficiently deliver its active component (TR2) into the bloodstream. Ceclazepide blocks gastric acid production by antagonizing the CCKB/gastrin receptor and has been investigated for use in acid-related gastrointestinal disorders and gastric neuroendocrine tumors. Compared to netazepide, ceclazepide is reported to be more selective and soluble, with easier formulation properties. The drug was developed by Trio Medicines and has undergone preclinical studies as well as early clinical evaluation[1][4][5].

Other names

(R)-1-[1-(4-acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea